Evidence map›Paper›PMID 35264631›Full record

ArticleSchizophrenia (Heidelberg, Germany)2022

Pattern of predictive features of continued cannabis use in patients with recent-onset psychosis and clinical high-risk for psychosis.

Nora Penzel, Rachele Sanfelici, Linda A Antonucci, Linda T Betz, Dominic Dwyer, Anne Ruef, Kang Ik K Cho, Paul Cumming, Oliver Pogarell, Oliver Howes and 20 more

Open access · diamondAbstract read
In one paragraph

Article in Schizophrenia (Heidelberg, Germany), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors at 20 institutions in 9 countries.

Nora PenzelUniversity of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Psychiatry and Psychotherapy, Cologne, Germany.ORCID 0000-0003-1624-386X
Rachele SanfeliciDepartment of Psychiatry and Psychotherapy, Ludwig-Maximilian-University, Munich, Germany.
Linda A AntonucciDepartment of Psychiatry and Psychotherapy, Ludwig-Maximilian-University, Munich, Germany.
Linda T BetzUniversity of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Psychiatry and Psychotherapy, Cologne, Germany.ORCID 0000-0003-1741-4069
Dominic DwyerDepartment of Psychiatry and Psychotherapy, Ludwig-Maximilian-University, Munich, Germany.
Anne RuefDepartment of Psychiatry and Psychotherapy, Ludwig-Maximilian-University, Munich, Germany.
Kang Ik K ChoDepartment of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Paul CummingDepartment of Nuclear Medicine, Bern University Hospital, Bern, Switzerland.
Oliver PogarellDepartment of Psychiatry and Psychotherapy, Ludwig-Maximilian-University, Munich, Germany.ORCID 0000-0001-6455-4190
Oliver HowesDepartment of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, De Crespigny Park, London, SE5 8AF, UK.
Peter FalkaiDepartment of Psychiatry and Psychotherapy, Ludwig-Maximilian-University, Munich, Germany.
Rachel UpthegroveInstitute for Mental Health, University of Birmingham, Birmingham, UK.
Stefan BorgwardtDepartment of Psychiatry (UPK), University of Basel, Basel, Switzerland.
Paolo BrambillaDepartment of Neurosciences and Mental Health, Fondazione IRCCUS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy.ORCID 0000-0002-4021-8456
Rebekka LencerDepartment of Psychiatry and Psychotherapy, University of Lübeck, Lübeck, Germany.
Eva MeisenzahlDepartment of Psychiatry and Psychotherapy, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany.
Frauke Schultze-LutterDepartment of Psychiatry and Psychotherapy, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany.ORCID 0000-0003-1956-9574
Marlene RosenUniversity of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Psychiatry and Psychotherapy, Cologne, Germany.
Theresa LichtensteinUniversity of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Psychiatry and Psychotherapy, Cologne, Germany.
Lana Kambeitz-IlankovicUniversity of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Psychiatry and Psychotherapy, Cologne, Germany.
Stephan RuhrmannUniversity of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Psychiatry and Psychotherapy, Cologne, Germany.ORCID 0000-0002-6022-2364
Raimo K R SalokangasDepartment of Psychiatry, University of Turku, Turku, Finland.
Christos PantelisMelbourne Neuropsychiatry Centre, University of Melbourne & Melbourne Health, Melbourne, VIC, Australia.ORCID 0000-0002-9565-0238
Stephen J WoodInstitute for Mental Health, University of Birmingham, Birmingham, UK.
Boris B QuednowExperimental and Clinical Pharmacopsychology, Department of Psychiatry, Psychotherapy, and Psychosomatics, Psychiatric Hospital of the University of Zurich, Lenggstr. 31, 8032, Zurich, Switzerland.
Giulio PergolaGroup of Psychiatric Neuroscience, Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari 'Aldo Moro', Bari, Italy.
Alessandro BertolinoGroup of Psychiatric Neuroscience, Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari 'Aldo Moro', Bari, Italy.
Nikolaos KoutsoulerisDepartment of Psychiatry and Psychotherapy, Ludwig-Maximilian-University, Munich, Germany.ORCID 0000-0001-6825-6262
Joseph KambeitzUniversity of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Psychiatry and Psychotherapy, Cologne, Germany. joseph.kambeitz@uk-koeln.de.ORCID 0000-0002-8988-3959
PRONIA Consortium
Ludwig-Maximilians-Universität München · DEUniversity of Cologne · DEUniversity of Turku · FIUniversity of Bari Aldo Moro · ITUniversity of Basel · CHUniversity of Birmingham · GBUniversity of Milan · ITUniversity of Münster · DEHeinrich Heine University Düsseldorf · DEUniversity of Udine · ITMax Planck Institute of Psychiatry · DEAzienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda · ITGeneral Electric (Germany) · DEThe University of Melbourne · AUUniversity of Bern · CHBirmingham Women’s and Children’s NHS Foundation Trust · GBIRCCS Eugenio Medea · ITKing's College London · GBOspedale San Paolo · ITBrigham and Women's Hospital · US

Funding

Deutsche Forschungsgemeinschaft (German Research Foundation) KA 4413/1-1Medical Research Council MC_U120097115Medical Research Council MR/N027078/1
6 · The paper itself

Abstract

Continued cannabis use (CCu) is an important predictor for poor long-term outcomes in psychosis and clinically high-risk patients, but no generalizable model has hitherto been tested for its ability to predict CCu in these vulnerable patient groups. In the current study, we investigated how structured clinical and cognitive assessments and structural magnetic resonance imaging (sMRI) contributed to the prediction of CCu in a group of 109 patients with recent-onset psychosis (ROP). We tested the generalizability of our predictors in 73 patients at clinical high-risk for psychosis (CHR). Here, CCu was defined as any cannabis consumption between baseline and 9-month follow-up, as assessed in structured interviews. All patients reported lifetime cannabis use at baseline. Data from clinical assessment alone correctly classified 73% (p < 0.001) of ROP and 59 % of CHR patients. The classifications of CCu based on sMRI and cognition were non-significant (ps > 0.093), and their addition to the interview-based predictor via stacking did not improve prediction significantly, either in the ROP or CHR groups (ps > 0.065). Lower functioning, specific substance use patterns, urbanicity and a lack of other coping strategies contributed reliably to the prediction of CCu and might thus represent important factors for guiding preventative efforts. Our results suggest that it may be possible to identify by clinical measures those psychosis-spectrum patients at high risk for CCu, potentially allowing to improve clinical care through targeted interventions. However, our model needs further testing in larger samples including more diverse clinical populations before being transferred into clinical practice.

Identifiers

PMID35264631
PMCPMC8907166
OpenAlexW4220788884

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.